Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model

• ClinicalTrials.gov Identifier: NCT05507567
• Recruitment Status: Completed
• First Posted: August 19, 2022
• Last Update Posted: May 19, 2023
• Sponsor: Pneumagen Ltd.
• Information provided by (Responsible Party): Pneumagen Ltd.

Study Description

Brief Summary:

Study to assess the efficacy and safety of a multiple dose regimen and a single dose regimen of intranasal Neumifil, administered prior to challenge with Influenza virus in healthy adult participants

Condition or disease	Intervention/treatment	Phase
Influenza Viral Infections	Drug: Neumifil; Drug: Placebo	Phase 2

Detailed Description:

This is a single-centre, randomized, double-blind, placebo-controlled study in healthy adult participants to assess the pre-exposure prophylactic antiviral activity of Neumifil via a human viral challenge model.

Participants will enter the quarantine unit on Day -4.

Participants will be randomized to receive either active (single dose), active (multiple dose) or placebo in a 3:3:4 ratio followed by influenza viral challenge on Day 0.

Participants will leave the unit on Day 8, provided that no virus is detected by a qualitative virus antigen test and the participant has no clinically significant symptoms. A final follow-up will be performed on Day 28.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 104 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Randomized, Double-blind, Placebo-controlled study
• Masking: Double (Participant, Investigator)
• Primary Purpose: Prevention
• Official Title: A Randomized, Double-blind, Placebo-controlled, Phase 2a Study To Assess the Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza, Via a Human Viral Challenge Model in Healthy Adult Participants
• Actual Study Start Date: August 12, 2022
• Actual Primary Completion Date: May 4, 2023
• Actual Study Completion Date: May 4, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: Neumifil multiple dose prophylactic treatment; Neumifil intranasal spray administered as 3 single daily doses prior to viral challenge	Drug: Neumifil; Liquid for intranasal spray administration
Experimental: Neumifil single dose prophylactic treatment; Neumifil intranasal spray administered as a single dose and blinded by placebo administered as two single daily doses. All administrations completed prior to viral challenge	Drug: Neumifil; Liquid for intranasal spray administration; Drug: Placebo; Liquid for intranasal spray administration
Placebo Comparator: Placebo; Intranasal spray administered as 3 single daily doses prior to viral challenge	Drug: Placebo; Liquid for intranasal spray administration

Outcome Measures

Primary Outcome Measures :

1. To evaluate the effect of Neumifil in reducing the incidence of symptomatic influenza infection compared to placebo [ Time Frame: Day 1 to Day 8 ]
   Incidence of 2 quantifiable qRT PCR samples on 2 consecutive days AND any symptoms of grade ≥2 at a single time point
2. To evaluate the effect of Neumifil in reducing the severity of symptoms compared to placebo [ Time Frame: Day 1 to Day 8 ]
   Change in Peak Total Symptom Score as measured by graded symptom scoring system collected 3 times daily; symptom questionnaire will be graded on a scale of 0-3 (grade 0: no symptoms; grade 1: just noticeable; grade 2: clearly bothersome from time to time but does not interfere with me doing my normal daily activities; grade 3: quite bothersome most or all of the time, and it stops me participating in activities).Lower score means better outcome.

Secondary Outcome Measures :

1. To evaluate the effect of Neumifil in reducing symptoms compared to placebo [ Time Frame: Day 1 to Day 8 ]
   Participants will complete a self-assessment symptom diary card
2. To evaluate the antiviral effect of Neumifil in reducing or shortening viral shedding when compared to placebo [ Time Frame: Day 1 to Day 8 ]
   Measurement of influenza viral load and duration of quantifiable measurements in nasal samples by qRT-PCR and tissue culture
3. To evaluate the effect of Neumifil in reducing nasal discharge [ Time Frame: Day 1 to Day 8 ]
   Measurement of total weight of mucus produced and number of tissues used by participants
4. To evaluate the safety of intranasal doses of Neumifil compared to placebo [ Time Frame: to Day 28 ]
   Occurrence of adverse events, solicited and unsolicited

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 55 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

1. Written informed consent signed and dated by the participant and the investigator obtained before any assessment is performed.
2. Adult male or female aged between 18 and 55 years old, inclusive, on the day prior to signing the consent form.
3. A total body weight ≥50 kg and body mass index (BMI) ≥18 kg/m2 and ≤35kg/m2.
4. In good health with no history, or current evidence, of clinically significant medical conditions, and no clinically significant test abnormalities that that will interfere with participant safety, as defined by medical history, physical examination, (including vital signs), ECG, and routine laboratory tests as determined by the investigator.
5. Participants will have a documented medical history either prior to entering the study or following medical history review with the study physician at screening.
6. Agree to use highly effective contraception
7. Serosuitable for the challenge virus

Exclusion Criteria:

1. History of, or currently active, symptoms or signs suggestive of upper or lower respiratory tract (URT, LRT) infection within 4 weeks prior to the first study visit.
2. Any history or evidence of any clinically significant or currently active cardiovascular, respiratory, dermatological, gastrointestinal, endocrinological, haematological, hepatic, immunological (including immunosuppression), metabolic, urological, renal, neurological, or psychiatric disease and/or other major disease that, in the opinion of the investigator, may interfere with a participant completing the study and necessary investigations. Includes a history of depression or anxiety.
3. Any participants who have smoked ≥ 10 pack years at any time.
4. Females who are pregnant or breastfeeding
5. Any history of anaphylaxis or history of severe allergic reactions to any foods, drugs, insect bites or stings or any known allergy to tetracycline antibiotics.
6. Venous access deemed inadequate for the phlebotomy and cannulation demands of the study.

7. a) Any significant abnormality altering the anatomy of the nose in a substantial way or nasopharynx that may interfere with the aims of the study and, in particular, any of the nasal assessments or viral challenge b) Any evidence of nasal inflammation or nasal polyps within the last month c) Any clinically significant history of epistaxis (large nosebleeds) within the last 3 months of the first study visit and/or history of being hospitalised due to epistaxis on any previous occasion.

   d) Any nasal or sinus surgery within 3 months of the first study visit. Prior or Concomitant Medications and Assessments

8. a) Evidence of vaccinations within the 4 weeks prior to the planned date of first dosing with IMP.

   b) Intention to receive any vaccination(s) before the last day of follow-up (with the exception of vaccinations recommended for COVID19 as defined by Medicines and Healthcare Regulatory Agency (MHRA)/government vaccination guidelines). No travel restrictions apply after the Day 28 (±3 days) follow-up visit.

   c) Receipt of influenza vaccine (or another IMP relating to treatment of influenza) in the last 6 months prior to the planned date of viral challenge OR a diagnosis of influenza or influenza-like illness confirmed by a physician within the last 2 months prior to screening.

9. Receipt of blood or blood products, or loss (including blood donations) of 550 mL or more of blood during the 3 months prior to the planned date of first dosing with IMP or planned during the 3 months after the final follow-up visit.

10. a) Receipt of any investigational drug within 3 months (or 5 half-lives of the IMP used in the other study, whichever is greater), prior to the planned date of first dosing with IMP.

    b) Receipt of 3 or more investigational drugs within the previous 12 months prior to the planned date of first dosing with IMP.

    c) Prior inoculation with a virus from the same virus-family as the challenge virus.

    d) Prior participation in another human viral challenge study with a respiratory virus in the preceding 3 months.

11. Use or anticipated use during the conduct of the study of concomitant medications
12. Confirmed positive test for drugs of misuse and cotinine on first study visit

13 Recent history or presence of alcohol addiction, or excessive use of alcohol

14. A FEV1 <80%, a FVC <80% predicted, or an FEV1/FVC ratio <0.7. 15. Positive HIV, hepatitis B virus, or hepatitis C virus test.

Contacts and Locations

Locations

United Kingdom

hVIVO Services Limited

London, United Kingdom, E1 2AX

Sponsors and Collaborators

Pneumagen Ltd.

Investigators

• Study Director: Geoff Kitson; gkitson@propharmapartners.com

More Information

• Responsible Party: Pneumagen Ltd.
• ClinicalTrials.gov Identifier: NCT05507567
• Other Study ID Numbers: PNG-NMF-201
• First Posted: August 19, 2022
• Last Update Posted: May 19, 2023
• Last Verified: May 2023

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Pneumagen Ltd.:

Influenza; Human Challenge; Prophylaxis

Additional relevant MeSH terms:

Influenza, Human; Virus Diseases; Respiratory Tract Infections; Infections; Orthomyxoviridae Infections; RNA Virus Infections; Respiratory Tract Diseases